Thermo Fisher Scientific awarded for excellence in 2022 CRO Leadership Awards

As an honoree, the PPD clinical research business will be featured in the 2022 CRO Leadership Awards issue in June.
The Thermo Fisher Scientific Building on Front Street will be put on the market soon. (photo: Peyton Furtado)

WILMINGTON, NC (WWAY) – The PPD clinical research business of Thermo Fisher Scientific has been recognized for excellence in the 2022 CRO Leadership Awards.

This is the 11th consecutive year the business has been honored through this award program, which is based on a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.

Recognized as a global industry leader, the business provides clinical development and analytical services from early development through regulatory approval and market access.

The business helps customers accelerate development and lower costs from scientific idea to approved medicine, providing product lifecycle management to ensure data integrity and patient safety.

Utilizing patient-centered strategies and data analytics, PPD clinical research services cover multiple therapeutic areas, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites, comprehensive laboratory services, innovative and decentralized trial designs, and a purpose-built delivery model for biotech customers.

In the 2022 CRO Leadership Awards, which recognize high-performing companies for exceptional customer service, the business earned recognition for its capabilities – including access to patient populations, data management and patient recruitment – and for compatibility, including responsiveness, project communications and customer service.

In addition, the business was recognized for quality, reliability and expertise.

The CRO Leadership Awards program is a partnership between Life Science Connect’s sister publications, Clinical Leader and Life Science Leader, and Industry Standard Research (ISR).

Each year, they assess more than 50 contract research organizations (CROs) on multiple performance metrics in ISR’s annual CRO Quality Benchmarking survey.

Survey participants included respondents from pharma and biotech companies who had worked directly with CROs in the prior 18 months.

As an honoree, the PPD clinical research business will be featured in the 2022 CRO Leadership Awards issue in June.

Categories: Industry Insider, Local, New Hanover, News, Top Stories